EP01.01-008 Expression of PD-L1 mRNA and Its Epigenetic Regulators: MicroRNA-17, -93 and -142 in Early Stages NSCLC Patients’ Plasma

Abstract

One of the leading treatment options for advanced non-small cell lung cancer (NSCLC) patients is immunotherapy based on immune checkpoint inhibitors, including programmed death ligand 1 (PD-L1) inhibitors. PD-L1 molecule expressed on tumor cells causes PD-1+ tumor infiltrating lymphocytes (TILs) exhaustion and thus escape from immune surveillance. Blockade of the PD-1/PD-L1 pathway by monoclonal antibodies enables restoration of the anti-tumor response. PD-L1 expression is regulated by epigenetic factors, e.g.: microRNAs (miRNAs).